Literature DB >> 2426266

Studies on the hepatic calcium-mobilizing activity of aluminum fluoride and glucagon. Modulation by cAMP and phorbol myristate acetate.

P F Blackmore, J H Exton.   

Abstract

The effects of submaximal doses of AlF4- to mobilize hepatocyte Ca2+ were potentiated by glucagon (0.1-1 nM) and 8-p-chlorophenylthio-cAMP. A similar potentiation by glucagon of submaximal doses of vasopressin, angiotensin II, and alpha 1-adrenergic agonists has been previously shown (Morgan, N. G., Charest, R., Blackmore, P. F., and Exton, J. H. (1984) Proc. Natl. Acad. Sci. U. S. A. 81, 4208-4212). When hepatocytes were pretreated with the protein kinase C activator 4 beta-phorbol 12 beta-myristate 13 alpha-acetate (PMA), the effects of AlF4- to mobilize Ca2+, increase myo-inositol 1,4,5-trisphosphate (IP3), and activate phosphorylase were attenuated. Treatment of hepatocytes with PMA likewise inhibits the ability of vasopressin, angiotensin II, and alpha 1-adrenergic agonists to increase IP3 and mobilize Ca2+ (Lynch, C. J., Charest, R., Bocckino, S. B., Exton, J. H., and Blackmore, P. F. (1985) J. Biol. Chem. 260, 2844-2851). In contrast, the ability of AlF4- or angiotensin II to lower cAMP or inhibit glucagon-mediated increases in cAMP was unaffected by PMA. The ability of AlF4- to lower cAMP was attenuated in hepatocytes from animals treated with islet-activating protein, whereas Ca2+ mobilization was not modified. These results suggest that the lowering of cAMP induced by AlF4- and angiotensin II was mediated by the inhibitory guanine nucleotide-binding regulatory protein of adenylate cyclase, whereas Ca2+ mobilization was not. Addition of glucagon, forskolin, or 8CPT-cAMP to hepatocytes raised IP3 and mobilized Ca2+. Both effects were blocked by PMA pretreatment, whereas cAMP and phosphorylase a levels were only minimally affected by PMA. The mobilization of Ca2+ induced by cAMP in hepatocytes incubated in low Ca2+ media was not additive with that induced by maximally effective doses of vasopressin, angiotensin II, or alpha 1-adrenergic agonists, indicating that the Ca2+ pool(s) affected by agents which increase cAMP is the same as that affected by Ca2+-mobilizing hormones which do not increase cAMP. These findings support the proposal that AlF4- mimics the effects of the Ca2+-mobilizing hormones in hepatocytes by activating a guanine nucleotide-binding regulatory protein (Np) which couples the hormone receptors to a phosphatidylinositol 4,5-bisphosphate (PIP2)-specific phosphodiesterase. They also suggest that Np, PIP2 phosphodiesterase, or a factor involved in their interaction is activated following phosphorylation by cAMP-dependent protein kinase and inhibited after phosphorylation by protein kinase C.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2426266

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  49 in total

1.  Guanine-nucleotide and hormone regulation of polyphosphoinositide phospholipase C activity of rat liver plasma membranes. Bivalent-cation and phospholipid requirements.

Authors:  S J Taylor; J H Exton
Journal:  Biochem J       Date:  1987-12-15       Impact factor: 3.857

2.  Glucagon, vasopressin and angiotensin all elicit a rapid, transient increase in hepatocyte protein kinase C activity.

Authors:  E K Tang; M D Houslay
Journal:  Biochem J       Date:  1992-04-15       Impact factor: 3.857

3.  AlF-4 inhibits the accumulation of Ca in the endoplasmic reticulum in intact myometrial strips, but not in the rabbit ear artery.

Authors:  L Missiaen; Y Kanmura; F Wuytack; L Raeymaekers; I Declerck; G Droogmans; R Casteels
Journal:  Pflugers Arch       Date:  1989-08       Impact factor: 3.657

4.  AlF4- reversibly inhibits 'P'-type cation-transport ATPases, possibly by interacting with the phosphate-binding site of the ATPase.

Authors:  L Missiaen; F Wuytack; H De Smedt; M Vrolix; R Casteels
Journal:  Biochem J       Date:  1988-08-01       Impact factor: 3.857

5.  Resensitization of hepatocyte glucagon-stimulated adenylate cyclase can be inhibited when cyclic AMP phosphodiesterase inhibitors are used to elevate intracellular cyclic AMP concentrations to supraphysiological values.

Authors:  G J Murphy; M D Houslay
Journal:  Biochem J       Date:  1988-01-15       Impact factor: 3.857

6.  Differential sensitivity of anti-IgM-induced and NaF-induced inositol phospholipid metabolism to serine protease inhibitors in BAL17 B lymphoma cells.

Authors:  J Mizuguchi; N Utsunomiya; M Nakanishi; Y Arata; H Fukazawa
Journal:  Biochem J       Date:  1989-11-01       Impact factor: 3.857

7.  Endothelial inositol phosphate generation and prostacyclin production in response to G-protein activation by AlF4-.

Authors:  M K Magnússon; H Halldórsson; M Kjeld; G Thorgeirsson
Journal:  Biochem J       Date:  1989-12-15       Impact factor: 3.857

8.  Frequency and amplitude enhancement of calcium transients by cyclic AMP in hepatocytes.

Authors:  C Schöfl; A Sanchez-Bueno; G Brabant; P H Cobbold; K S Cuthbertson
Journal:  Biochem J       Date:  1991-02-01       Impact factor: 3.857

9.  Activation of the inositol trisphosphate second messenger system by cAMP in a mouse fibroblast cell line.

Authors:  V J Horn; P A Sheehy; M B Goodman; I S Ambudkar
Journal:  Mol Cell Biochem       Date:  1991-02-27       Impact factor: 3.396

10.  Multiple mechanisms by which protein kinase A potentiates inositol 1,4,5-trisphosphate-induced Ca2+ mobilization in permeabilized hepatocytes.

Authors:  G Hajnóczky; E Gao; T Nomura; J B Hoek; A P Thomas
Journal:  Biochem J       Date:  1993-07-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.